Finanzen von Quantum Biopharma Ltd (QNTM)QNTMQuantum Biopharma Ltd

Evaluating the bottom line, Quantum Biopharma Ltd maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -429.58%, provide a clear picture of how effectively QNTM converts its operational activities into shareholder value.

In the context of the broader market, QNTM competes directly with industry leaders such as MCRB and BSEM. With a market capitalization of $16.91M, it holds a significant position in the sector. When comparing efficiency, QNTM's gross margin of N/A stands against MCRB's 18.89% and BSEM's 52.55%. Such benchmarking helps identify whether Quantum Biopharma Ltd is trading at a premium or discount relative to its financial performance.

Quantum BioPharma has been experiencing significant financial challenges, with a net income loss of -13560299 USD in Q1 2026 and a gross profit of -129298 USD in Q1 2025. The current ratio has dropped to 0.63 in Q1 2026, indicating liquidity issues, and the debt-to-equity ratio is at 15.81%, showing a manageable level of debt.